SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors express significant frustration and skepticism toward the Board's decision to accept an all-cash acquisition offer, which many feel drastically undervalues the company's cash position, core drug assets, and future growth potential. The community is actively debating the merits of the deal, with some shareholders organizing to oppose the tender offer and others seeking legal avenues to challenge what they characterize as an unethical 'fire sale' by management.

MMTec, Inc. engages in the holding of an equity interest in MM Future. It operates through the Gujia, MM Future and HC Securities and MM Global. The Gujia, MM Future and HC Securities segment provide market data services and consulting services. The MM Global segment is involved in introducing a broker that clears all transactions through a clearing broker dealer and earns commission income, placement agent services fee, and other related income from customers. The company was founded on January 4, 2018 and is headquartered in Hong Kong.

Mmtec Inc

Mmtec Inc is generating significant market interest as traders speculate on potential short squeeze dynamics and the company's efforts to maintain its NASDAQ listing status. Community discussions are heavily focused on the stock's extreme volatility and its tendency to mirror past microcap momentum plays, with participants actively debating the risks of delisting against the possibility of aggressive rallies.

Amtech Systems, Inc. engages in the manufacture of semiconductors and capital equipment. It operates through the Semiconductor and Material and Substrate segments. The Semiconductor segment involves the designing, manufacturing, selling, and servicing of thermal processing equipment and related controls for use by semiconductor manufacturers, and in electronics, automotive, and other industries. The Material and Substrate segment produces consumables and machinery for lapping and polishing materials, such as sapphire substrates, optical components, silicon wafers, and numerous types of crystal materials, ceramics, and metal components. The company was founded by Jong S. Whang in October 1981 and is headquartered in Tempe, AZ.

Amtech Systems Inc.

Amtech Systems is gaining momentum as investors eye its strategic role in the AI-driven semiconductor supply chain, specifically through its exposure to advanced packaging and wafer substrate fabrication. While the community remains optimistic about the company's long-term growth potential and turnaround narrative, discussions are increasingly balanced by caution regarding recent earnings performance and sector-wide cyclical risks.

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YDES is currently garnering significant attention from retail traders due to its status as a recent Nasdaq uplisting with a remarkably low float, leading to discussions about potential volatility and short-squeeze setups. The community is closely monitoring the stock's price action alongside its associated warrants, debating whether current valuations present a mispricing opportunity or a speculative trap.

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LENSAR Inc

LENSAR Inc. shares are under significant pressure following the mutual termination of its merger agreement with Alcon, a decision prompted by mounting regulatory opposition from the FTC. The community is actively debating the company's standalone future, weighing concerns over operational liquidity and intense market competition against the potential durability of its recurring revenue model and ALLY system adoption.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending due to its unique 'PvE' (Player-versus-Environment) narrative, which emphasizes long-term community conviction over short-term speculative trading. Supporters are actively highlighting the project's 'Airlock' mechanismwhere nearly half of the supply is voluntarily lockedas proof of a committed, cult-like movement that is actively outperforming typical market volatility.

Ethereum Classic

Ethereum Classic is experiencing renewed community focus as investors speculate on a long-awaited breakout, with many sentiment-driven discussions highlighting the contrast between the token's historical performance and its current suppressed price action. Traders are actively debating the timing of a potential trend reversal, frequently citing broader crypto market catalysts and comparing its utility to other established proof-of-work assets.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing satirical project that has transitioned onto the Solana network, with the community positioning it as a cultural successor to early Bitcoin lore. Supporters are actively discussing its 15-year history and perceived potential for generational wealth, while debates continue between those dismissing it as a meme-driven joke and those convinced it represents a unique opportunity in the current market cycle.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid community speculation about an impending short squeeze, fueled by significant short interest and anticipation surrounding upcoming pilot plant results and a replacement preliminary economic assessment. Investors are intensely debating the impact of these pending disclosures on the company's valuation, while monitoring broader sector volatility and geopolitical developments in Greenland.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently rallying on optimism surrounding potential ETF approval and its dominant position as a leading decentralized perpetual exchange. The community is actively discussing its rapid growth in trading volume and its role as a key infrastructure player in the broader decentralized finance ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Wall Street Zen lowered Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday...

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of...

Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report issued on Tuesday, March...

Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average...

FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright upped their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March...

Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00

Stifel Nicolaus decreased their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday...

Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. The company had revenue of $11.04 million during the quarter...

Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research report on Sunday...

Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday

Pyxis Oncology (NASDAQ:PYXS) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Current Price	$1.70
Prev Close	$1.61
Open	$1.61
Dividend Yield	0.00%
50-Day Moving Average	$1.47
Beta	1.46
Avg. Volume	346,624.66
PE Ratio	-1.32

52-Week High	$5.55
52-Week Low	$0.873
Market Capitalization	$101.16M
EPS (Annual)	-$1.28
Price to Book	2.00
Revenue Per Employee	$247,464.29

PYXS
Pyxis Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PYXS News

PYXSPyxis Oncology Inc